APLS - アペリス・ファ―マシュ―ティカルズ （Apellis Pharmaceuticals Inc.） アペリス・ファ―マシュ―ティカルズAPLSのチャート
APLSの企業情報
| symbol | APLS |
|---|---|
| 会社名 | Apellis Pharmaceuticals Inc （アペリス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アペリス・ファーマスーティカルズ(Apellis Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は自己免疫および炎症性疾患の治療化合物の発見・開発に焦点を当てる。同社のリード化合物は補体カスケードにある中心タンパク質である補体成分3（C3）を阻害するように設計される。同社は皮膚下の組織への注射である皮下注射による発作性夜間ヘモグロビン尿症（PNH）の治療用APL-2を開発中である。同社は眼内への注射である硝子体内注射により、地図状萎縮（GA）および加齢黄斑変性（AMD）の治療用APL-2を開発中である。同社は吸入投与による慢性閉塞性肺疾患（COPD）の治療用APL-1を開発中である。 アペリス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、免疫系の構成要素である補体系の阻害を介して、補体カスケ―ドの中心タンパク質であるC3のレベルで、疾患を治療する化合物の開発に従事する。同社は、補体依存性の自己免疫疾患や炎症性疾患を治療するために開発する。本社所在地はケンタッキ―州クレストウッド。 Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. |
| 本社所在地 | 6400 Westwind Way Suite A Crestwood KY 40014 USA |
| 代表者氏名 | Gerald Chan ジェラルドチャン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 502-241-4114 |
| 設立年月日 | 40057 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 39人 |
| url | www.apellis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/apls |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -84.50572 |
| 終値（lastsale） | 16.01 |
| 時価総額（marketcap） | 899411765.24 |
| 時価総額 | 時価総額（百万ドル） 888.73790 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 661.65977 |
| 当期純利益 | 当期純利益（百万ドル） -84.89977 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Apellis Pharmaceuticals Inc revenues was not reported. Net loss increased from $21.2M to $55.1M. Higher net loss reflects Research and Development increase from $17.7M to $44.9M (expense) General and Administrative increase from $3.5M to $10M (expense) Interest income (expense) net increase from $0K to $83K (expense). |
APLSのテクニカル分析
APLSのニュース
Apellis Pharmaceuticals Is Said To Attract Takeover Interest - Bloomberg 2023/04/02 16:37:01 Investing.com
https://www.investing.com/news/pro/apellis-pharmaceuticals-is-said-to-attract-takeover-interest--bloomberg-432SI-3047133
Apellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy Market 2023/03/24 18:37:39 Seeking Alpha
Apellis Pharmaceuticals received FDA approval for Syfovre (pegcetacoplan injection) for geographic atrophy secondary to age-related macular degeneration. Read more here.
Is Apellis Pharmaceuticals Inc. (NASDAQ:APLS) stock a better investment at this time? 2023/03/16 16:40:00 US Post News
Apellis Pharmaceuticals Inc. (APLS)’s stock has witnessed a price declined of -3.31% from the previous close with its current price standing at $63.36. Its current price is -10.45% under its 52-week high of $70.75 and 90.16% more than its 52-week low of $33.32. Based on the past 30-day period, the stock price is -11.20% below […]
Apellis Pharmaceuticals'' Empaveli sNDA action date extended by FDA 2023/03/16 03:34:42 Seeking Alpha
The FDA extended by an undetermined period its review of an sNDA from Apellis Pharmaceuticals for Empaveli. Click here for more.
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) 4.01% Incline Turns Investors Away 2023/03/15 13:00:00 Stocks Register
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) price closed higher on Tuesday, March 14, jumping 4.01% above its previous close. A look at the daily price movement shows that the last close reads $62.66, with intraday deals fluctuated between $63.63 and $66.01. The company’s 5Y monthly beta was ticking 1.20. Taking into account the 52-week price action we … Apellis Pharmaceuticals Inc. (NASDAQ: APLS) 4.01% Incline Turns Investors Away Read More »
Apellis files for FDA approval of pegcetacoplan to treat eye disorder 2022/06/01 12:05:07 Seeking Alpha
Apellis Pharmaceuticals (APLS) said it filed an application with the U.S
Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here''s What You Need To Know 2022/05/24 16:09:33 Benzinga
Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ: APLS ) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3% over the last 24 hours, at $43.40 per share. A move to $84.00 would account for a 93.55% increase from the current share price. About Apellis Pharmaceuticals Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, … Full story available on Benzinga.com
Apellis Pharmaceuticals Inc. (APLS) Is A Buy Stock For Small Caps – Analysts 2022/05/18 14:30:00 Marketing Sentinel
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) has a beta value of 1.67 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $4.17B, closed the last trade at $42.16 per share which meant it gained $3.32 on the day or 8.55% during that session. The APLS stock price is -73.15% … Apellis Pharmaceuticals Inc. (APLS) Is A Buy Stock For Small Caps – Analysts Read More »
Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow (NASDAQ:APLS) 2022/05/06 21:42:47 Seeking Alpha
The following slide deck was published by Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2022/05/06 20:23:00 GlobeNewswire
WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of May 2, 2022, as equity inducement awards outside of the company''s 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) Is 33.25% Above Its 52-Week Low, But How Long Will It Remain So? 2022/02/05 16:30:00 Marketing Sentinel
In last trading session, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) saw 0.58 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $41.20 trading at $0.91 or 2.26% at ring of the bell on the day assigns it a market valuation of $3.87B. That closing price of APLS’s stock is … Apellis Pharmaceuticals Inc. (NASDAQ:APLS) Is 33.25% Above Its 52-Week Low, But How Long Will It Remain So? Read More »
Apellis Pharmaceuticals (APLS) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference 2022/01/12 20:26:43 Seeking Alpha
David O. Watson Sells 10,571 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock 2021/12/24 13:36:42 Dakota Financial News
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 10,571 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, December 22nd. The stock was sold at an average price of $47.81, for a total transaction of $505,399.51. The sale was disclosed in a filing with the SEC, which can be accessed through the […]
SG Americas Securities LLC Has $6.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) 2021/12/24 10:48:43 ETF Daily News
SG Americas Securities LLC lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 637.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 184,014 shares of the companys stock after buying an additional 159,061 shares during the period. SG Americas Securities LLC [] The post SG Americas Securities LLC Has $6.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) appeared first on ETF Daily News .